Can psilocybin cure alcoholism?

No clinical trial uses the word 'cure' — but the NYU alcohol use disorder data is remarkable. 2 psilocybin sessions reduced drinking by 83% or resulted in abstinence in trial participants at 8-month follow-up. The Hopkins team reported similar results. Whether these effects are durable beyond 1–2 years is still being studied in follow-up research. The mechanism — resetting default mode network rumination loops and increasing psychological flexibility — is thought to address the underlying compulsive pattern rather than just suppress cravings.

How does psilocybin treat addiction?

Psilocybin is believed to treat addiction through several mechanisms: (1) Default Mode Network disruption breaks the ruminative 'craving loops' that maintain addiction; (2) The psychedelic experience creates a period of heightened neuroplasticity where new behavioral patterns can form; (3) Mystical/awe experiences correlate strongly with lasting behavioral change; (4) Emotional processing allows people to address the underlying trauma, anxiety, or depression driving addictive behavior; (5) BDNF upregulation supports lasting structural brain changes.

What addictions has psilocybin been studied for?

Psilocybin has been studied for: alcohol use disorder (strongest evidence — NYU, Hopkins), nicotine/tobacco cessation (Hopkins pilot, 80% abstinence), cocaine use disorder (Hopkins ongoing), opioid use disorder (limited early data), methamphetamine use disorder (early exploration), and gambling disorder (theoretical, no major trials yet). Alcohol and nicotine have the most completed trial data; opioid and cocaine trials are actively enrolling.

Can I join a psilocybin addiction clinical trial?

Yes. Multiple trials are actively enrolling. NYU's psilocybin + AUD trial, Hopkins' cocaine use disorder trial, and several smoking cessation trials have open enrollment. Search ClinicalTrials.gov for 'psilocybin alcohol' or 'psilocybin addiction' filtered to 'Recruiting'. Participation is free and includes compensation. Requirements typically include a confirmed addiction diagnosis, 30+ day history, willingness to do a medication washout period, and no psychosis history.

Psilocybin for Addiction 2026 — Alcohol, Nicotine & Opioids

Q: Does psilocybin help with addiction?

Clinical trials show striking results. The NYU alcohol use disorder trial found 83% of participants had reduced drinking or abstinence after 2 psilocybin sessions — the highest response rates ever recorded in AUD research. The Johns Hopkins nicotine/smoking cessation pilot showed 80% abstinence at 6 months (vs 35% for nicotine replacement therapy). Cocaine, opioid, and methamphetamine trials are in earlier stages but show promising early data.

Q: Is psilocybin FDA-approved for addiction?

No. Psilocybin is not FDA-approved for any addiction indication as of 2026. All access is through clinical trials (free), Oregon/Colorado licensed service centers (legal but not medical), or international treatment centers. OOTWOracle's 8-agent AI predicts 52% probability of psilocybin FDA approval for depression by 2028, after which off-label addiction use and specific addiction NDAs become more feasible.

83%

AUD — reduced drinking/abstinence (NYU RCT)

80%

Smoking cessation at 6 months (Hopkins)

46M

Americans with substance use disorders

2 sessions

Treatment protocol in most addiction trials

Important Context: These trial results are in structured research settings with preparation, therapist support during sessions, and integration therapy afterward. The "psilocybin alone" effect is not the same as the full therapeutic protocol. Most trials use 2 high-dose psilocybin sessions embedded within 8–12 weeks of motivational enhancement therapy. Results reflect the combined protocol, not the drug in isolation.

The Evidence — What the Trials Actually Show

Phase 2 RCT — 2022 (NEJM)

83%

Alcohol Use Disorder — NYU

93 participants. 2 psilocybin sessions vs. diphenhydramine control over 12 weeks motivational therapy. 83% reduced drinking or abstinence vs. 51% control at 8 months. Bogenschutz et al., NEJM.

Phase 2 RCT — 2022 (JAMA)

48%

Alcohol Use Disorder — Hopkins

95 participants. 2 psilocybin sessions. 48% abstinence in psilocybin arm vs 24% placebo at 32 weeks. Secondary: 83% reduction in heavy drinking days. Bogenschutz et al., JAMA Psych.

Phase 2 Pilot — 2014

80%

Nicotine/Smoking Cessation — Hopkins

15 participants. 2–3 psilocybin sessions within cognitive behavioral therapy. 80% biochemically verified abstinence at 6 months. 67% at 12 months. Johnson et al., J Psychopharmacol.

Phase 2 — Ongoing 2024+

TBD

Cocaine Use Disorder — Hopkins

Phase 2 RCT ongoing (NCT03913234). 82 participants. Primary: cocaine use by urine screen. Based on open-label data showing significant reductions. Results expected 2026–2027.

Phase 2 — Active

TBD

Opioid Use Disorder — UCSF

Psilocybin-assisted therapy for opioid use disorder, including patients on buprenorphine maintenance. NCT05524415. Targeting comorbid depression + OUD. Results 2027.

Phase 2 — Active

TBD

AUD + Depression Comorbidity — NYU

Extended NYU AUD work specifically targeting dual diagnosis (AUD + MDD), the most common and treatment-resistant presentation. 2 psilocybin sessions + therapy. Enrolling 2025–2026.

Psilocybin vs. Existing Addiction Treatments

Treatment	Substance	Abstinence/Response	Sessions	FDA Approved
Psilocybin (NYU RCT)	Alcohol	83% reduced/abstinent at 8mo	2 sessions	❌ No
Naltrexone (best standard care)	Alcohol	~35–40% abstinence	Daily pill	✅ Yes
Acamprosate	Alcohol	~36% abstinence	Daily pill	✅ Yes
Psilocybin (Hopkins pilot)	Nicotine	80% at 6mo	2–3 sessions	❌ No
Varenicline (Chantix)	Nicotine	~33% at 6 months	Daily pill 12wks	✅ Yes
Nicotine replacement therapy	Nicotine	~25–35% at 6mo	Ongoing	✅ Yes
Buprenorphine/naloxone	Opioids	~50% retention in tx	Daily	✅ Yes
MDMA-assisted (PTSD-related AUD)	Alcohol/PTSD	~67% PTSD → secondary AUD improvement	3 sessions	❌ No (CRL)

Evidence by Substance — Where Are We in 2026?

Strong Evidence

🍺 Alcohol Use Disorder

Two well-powered Phase 2 RCTs published in NEJM (2022) and JAMA Psychiatry (2022). Effect sizes significantly outperform every FDA-approved AUD medication. Phase 3 trials in planning. 29M Americans affected.

Strong Evidence

🚬 Nicotine/Tobacco

Hopkins pilot (2014, n=15) shows 80% abstinence — more than twice the rate of varenicline. Larger Phase 2 trials underway. 34M adult smokers in the US. A positive Phase 3 here would be commercially transformative.

Moderate Evidence

🤍 Cocaine Use Disorder

Open-label data promising. Phase 2 RCT at Hopkins (n=82) ongoing. Cocaine has no FDA-approved medications — any effective intervention would meet enormous unmet need. Results expected 2026–2027.

Moderate Evidence

💊 Opioid Use Disorder

Early-phase evidence. UCSF trial explores psilocybin + buprenorphine combination, addressing the depression/trauma driving OUD relapse. More complex than AUD given opioid physiology. 2.7M Americans with OUD.

Early Stage

⚡ Methamphetamine

No completed RCTs. Preclinical and observational data. Meth has no FDA-approved medications — the highest unmet need category. Phase 1 safety trials initiated 2025.

Early Stage

🎰 Behavioral Addictions

Gambling disorder, food addiction, compulsive use — theoretical foundation (DMN disruption breaks compulsive loops) is strong but no completed human trials. Likely next expansion after substance trials.

How Psilocybin Treats Addiction — The Mechanism

The standard addiction framework focuses on craving management and relapse prevention. Psilocybin appears to work differently — not by suppressing cravings but by resetting the underlying neural architecture that makes addictive behavior compulsive.

The Default Mode Network Reset

Addiction is strongly associated with hyperactive Default Mode Network (DMN) activity — the brain's "autopilot" network responsible for self-referential thought and habitual behavior. Psilocybin significantly suppresses DMN activity during the session, and this suppression is associated with lasting reductions in craving and compulsive use patterns post-session.

Neuroplasticity Window

5-HT2A activation triggers a burst of neuroplasticity — the brain's capacity to form new connections and rewire established patterns. When combined with psychotherapy during and after this window, the evidence suggests patients can form new behavioral responses to triggers that previously drove drug-seeking behavior.

The Mystical Experience Correlation

In virtually every addiction trial, the strength of the "mystical experience" during the psilocybin session is the single strongest predictor of lasting outcomes. Participants who report complete or near-complete mystical experiences show dramatically better results than those who don't. This finding — replicated across alcohol, nicotine, and cancer anxiety trials — suggests the psychological quality of the experience is mechanistically important, not just incidental.

Addressing Root Causes

Many addiction patterns are driven by unresolved trauma, anxiety, depression, or chronic pain. Psilocybin appears to create a window where these underlying drivers become accessible for processing in a way that standard pharmacotherapy cannot facilitate. The result is that addiction treatment "sticks" because the source conditions are being addressed alongside the behavioral pattern.

Active Clinical Trials — How to Enroll

Trial	Substance	Sponsor	Location	Status
Psilocybin + AUD (Phase 2 ext.)	Alcohol	NYU Langone	New York, NY	Enrolling
Psilocybin + AUD + MDD	Alcohol + Depression	NYU / Hopkins	Multiple	Enrolling
Psilocybin + CUD	Cocaine	Johns Hopkins	Baltimore, MD	Enrolling
Psilocybin + OUD + buprenorphine	Opioids	UCSF	San Francisco, CA	Enrolling
Psilocybin smoking cessation Phase 2	Nicotine	Hopkins/UCL	Multiple	Enrolling
COMP360 + AUD	Alcohol	COMPASS Pathways	Multiple EU+US	Phase 2 planning

How to Enroll: Search ClinicalTrials.gov for "psilocybin" + your substance (e.g., "psilocybin alcohol" or "psilocybin cocaine"). Filter by "Recruiting". Most trials require: documented substance use disorder diagnosis, 30+ day history, ability to commit to 8–12 weeks at the site location, no psychosis history, and a washout period from other medications (usually 2 weeks). Compensation: $200–$500. All therapy and medication costs are free.

OOTWOracle Predictions — Addiction Approval Timeline

🔮 8-Agent AI Oracle — Psilocybin Addiction Pathway

Psilocybin AUD Phase 3 initiated by 2027

61%

Psilocybin NDA filed for AUD by 2030

38%

Psilocybin FDA approval (depression) by 2028 — enables off-label AUD use

52%

Nicotine cessation NDA filed by 2029

29%

Insurance coverage for psilocybin AUD treatment within 2yr of approval

58%

Cocaine/meth psilocybin approval by 2033

21%

4 Agent Views — Addiction Research Outlook

🏛️ FDA Regulatory Reviewer

"The NYU alcohol trial in NEJM is a landmark paper. The effect size over diphenhydramine active placebo is genuinely unusual for this therapeutic area — AUD trials typically show 5–10 percentage point differences between arms, not 30+. The challenge for NDA review is the complex therapeutic protocol: you can't separate the psilocybin from the therapy. This is the same issue MDMA faced. FDA will need to determine whether to approve 'psilocybin' or 'psilocybin-assisted therapy' as a system — and the latter requires REMS and certified therapist training programs."

🧪 MAPS Researcher

"What the addiction data is telling us is that the therapeutic model matters as much as the molecule. Both MDMA and psilocybin show exceptional results for trauma-driven conditions (PTSD, AUD, OUD) when embedded in structured therapeutic frameworks — and much weaker effects when administered without that container. The implication for FDA is challenging: how do you run a Phase 3 for a therapy system where the therapist is part of the intervention? We're essentially asking FDA to approve a new category."

💰 Biotech Investor

"The commercial opportunity in addiction is enormous — arguably larger than depression. 29 million Americans with AUD, 34 million smokers, 2.7 million with OUD. Current medications are modestly effective at best. If psilocybin delivers 80% smoking cessation in a Phase 3, that's a multi-billion dollar market disruption of nicotine replacement products. The problem is the 2–3 session structure; it's hard to build a recurring revenue model around a treatment that works in 2 sessions. Expect pharma companies to pursue companion therapy software subscriptions to capture lifetime value."

📰 Investigative Journalist

"The opioid angle is where I'd focus attention in 2026–2028. Psilocybin for alcohol or nicotine is compelling but not urgent at the policy level — we have treatments for those. For opioids, where fentanyl overdoses are killing 100,000 Americans a year and buprenorphine barely scratches retention rates, the political urgency is different. If a Phase 2 opioid trial shows results anywhere close to the AUD data, expect emergency legislative action and FDA fast-track designations that compress the approval timeline from 10 years to 4 or 5."

Frequently Asked Questions

Does psilocybin help with addiction? ▼

Yes — the clinical evidence is remarkably strong, particularly for alcohol and nicotine. The NYU alcohol trial published in NEJM showed 83% reduced drinking or abstinence after 2 psilocybin sessions, vs 51% for active placebo. The Hopkins nicotine pilot showed 80% abstinence at 6 months, more than twice the rate of the best current medication. For cocaine and opioids, Phase 2 trials are ongoing with early promising results.

Is psilocybin FDA-approved for addiction? ▼

No. Psilocybin is Schedule I and not FDA-approved for any addiction indication. Access is through clinical trials (free, with compensation) or Oregon/Colorado licensed service centers (legal, not medical). OOTWOracle predicts 52% probability of psilocybin FDA approval for depression by 2028 — which would enable off-label prescribing for addiction while dedicated addiction NDAs proceed through Phase 3.

How does psilocybin treat alcoholism? ▼

Psilocybin appears to address alcoholism through Default Mode Network disruption (breaking compulsive behavior loops), neuroplasticity (making it easier to form new patterns), mystical/peak experiences (which correlate strongly with lasting change), and facilitated processing of underlying trauma or emotional pain driving the drinking. Unlike naltrexone or acamprosate which reduce cravings pharmacologically, psilocybin seems to address the root compulsive architecture — which may explain why effects persist for months after just 2 sessions.

Can psilocybin help with opioid addiction? ▼

Psilocybin for opioid use disorder is in Phase 1/2 trials. The UCSF trial (NCT05524415) is exploring psilocybin alongside buprenorphine maintenance — addressing the depression and trauma that drive relapse even in people on medication-assisted treatment. Early results are expected 2027. The mechanistic rationale is strong — OUD is heavily trauma-driven, and psilocybin's trauma processing effects are among its most documented clinical features.

Is psilocybin better than methadone or naltrexone for opioid addiction? ▼

We don't know yet — psilocybin hasn't been directly compared to gold-standard OUD treatments in a powered RCT. What the early data suggests is a different use case: psilocybin may be most effective as an adjunct to medication-assisted treatment (MAT) — helping people engage with treatment, process the underlying trauma driving relapse, and achieve better outcomes alongside buprenorphine or naltrexone, rather than replacing them. Direct comparisons require Phase 3 data that doesn't exist yet.

When will psilocybin be available as an addiction treatment? ▼

OOTWOracle predicts 61% probability of a psilocybin AUD Phase 3 trial initiated by 2027. An NDA filing is 38% probable by 2030 for AUD. However, if psilocybin gets FDA approval for depression (52% by 2028), off-label prescribing for addiction by physicians would likely begin almost immediately — especially for the dual-diagnosis population. Oregon and Colorado service centers already provide legal access today, and many practitioners are already working with clients on addiction-adjacent issues in those frameworks.

Related Research

🧠 Psilocybin for Depression 😌 Psilocybin for Anxiety 🍄 FDA Approval Tracker 🔬 Clinical Trials — How to Enroll 💊 MDMA Therapy 💰 Therapy Cost Guide 🌿 Ibogaine for Addiction 📚 All Topics

📡 OOTWOracle — Daily AI predictions on psychedelic medicine regulation

8 AI agents · 3-round deliberation · Updated every day. Track the regulatory signals that matter.

View Today's Oracle →